KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Gains from Sales and Divestitures (2021 - 2023)

Ginkgo Bioworks Holdings posted quarterly Gains from Sales and Divestitures of $27.2 million for Q2 2023, up 6183.36% year-on-year from $433160.0 in Q2 2022, and up 130.2% on a QoQ basis from $11.8 million in Q1 2023.

Ginkgo Bioworks Holdings (DNA) has 3 years of Gains from Sales and Divestitures data on file, last reported at $27.2 million in Q2 2023.

  • For the quarter ending Q2 2023, Gains from Sales and Divestitures rose 6183.36% year-over-year to $27.2 million; the trailing twelve-month figure through Jun 2023 stood at $27.2 million (up 6183.36% YoY), and the FY2022 full-year result was $178531.0, down 24.49% from the prior year.
  • Gains from Sales and Divestitures for Q2 2023 stood at $27.2 million, up from $11.8 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $27.2 million in Q2 2023 and bottomed at $44632.0 in Q1 2022.
  • The 3-year median for Gains from Sales and Divestitures is $433160.0 (2022), against an average of $9.1 million.
  • The widest annual swing landed in 2022, when Gains from Sales and Divestitures declined 24.49%; it then soared 26389.96% in 2023.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $236427.0 in 2021, then declined by 24.49% to $178531.0 in 2022, then surged by 15144.97% to $27.2 million in 2023.
  • The last three Gains from Sales and Divestitures figures came in at $27.2 million (Q2 2023), $11.8 million (Q1 2023), and $178531.0 (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Ginkgo Bioworks Holdings 542.03 Mn 542.03 Mn 16.38 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 27.22 Mn
Jun 30, 2023 27.22 Mn
Mar 31, 2023 11.82 Mn
Mar 31, 2023 11.82 Mn
Dec 31, 2022 178,531.00
Dec 31, 2022 178,531.00
Sep 30, 2022 23.48 Mn
Sep 30, 2022 23.48 Mn
Jun 30, 2022 433,160.00
Jun 30, 2022 433,160.00
Mar 31, 2022 44,632.00
Mar 31, 2022 44,632.00
Dec 31, 2021 236,427.00
Dec 31, 2021 236,427.00